Drug Search Results
More Filters [+]

Griseofulvin

Alternative Names: griseofulvin, grisactin, grifulvin v, fulvicin p/g, fulvicin p/g 165, fulvicin p/g 330, gris-peg, grisactin ultra, ultragris-330, fulvicin-u/f, ultragris-165
Latest Update: 2023-03-02
Latest Update Note: News Article

Product Description

Griseofulvin is used to treat skin infections such as jock itch, athlete's foot, and ringworm; and fungal infections of the scalp, fingernails, and toenails. (Sourced from: https://medlineplus.gov/druginfo/meds/a682295.html)

Mechanisms of Action: Tubulin Inhibitor,Mitosis Inhibitor,Fungal Growth Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Bangladesh | Brazil | Canada | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | France | Germany | Hong Kong | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Malaysia | Malta | Morocco | New Zealand | Pakistan | Peru | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | South Africa | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Griseofulvin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events